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Abstract 
A variety of 2-(aminomethyl)aziridines was prepared and converted into the corresponding 1,2,3-
triaminopropanes through a novel, microwave-assisted and regioselective ring opening by 
diethylamine in acetonitrile. Antiplasmodial assays revealed antimalarial activity for 2-[(1,2,4-triazol-
1-yl)methyl]aziridines and 2-(N,N-diethylaminomethyl)aziridines, as well as for the corresponding 1-
(diethylamino)propanes obtained through ring opening, pointing to the relevance of both the 2-
(aminomethyl)aziridine and the 1,2,3-triaminopropane unit as novel antimalarial pharmacophores. 
Keywords: aziridines; aziridinium salts; ring opening; triaminopropanes; antimalarial agents 
 
Introduction 
With 247 million clinical cases and nearly one million deaths in 2008, mostly among African 
children, malaria remains a major issue in health control [1]. Quinoline containing 
compounds, such as the potent and inexpensive chloroquine (CQ) [2,3,4] have a long tradition 
in the treatment of malaria, and systematic modification has led to a variety of antimalarial 
drugs with diverse substitutions around the quinoline ring [5,6]. However, the spread of 
chloroquine-resistant Plasmodium falciparum strains has dashed hopes of global malaria 
eradication and has complicated the clinical management of malaria in endemic areas. 
Consequently, many efforts are devoted to the design and synthesis of novel and structurally 







diverse compounds with potential antimalarial activity. Recently, the β-amino alcohol moiety 
has been introduced as a promising antimalarial pharmacophore, and the synthesis of a 
number of novel aminopropanols with significant antimalarial activity has revealed the 
medicinal importance of this class of glycerol analogues [7,8,9]. Their aza-derivatives, i.e. 
1,2,3-triaminopropanes, however, have not been the subject of antimalarial screening up to 
now. 
In this paper, the preparation and biological evaluation of novel 2-(aminomethyl)aziridines 
and 1,2,3-triaminopropanes is described as potential new lead compounds within the 
framework of malaria management and treatment. 
The aziridine moiety represents one of the most valuable three-membered ring systems in 
organic chemistry [10,11,12,13,14,15,16,17], and the regiocontrolled ring opening of C-
substituted aziridines constitutes a powerful approach towards the preparation of a large 
variety of nitrogen-containing target compounds. In contrast to their activated counterparts, 
non-activated aziridines have been evaluated to a limited extent up to now, both from a 
synthetic and a pharmacological point of view. Due to the presence of an electron-donating 
substituent at nitrogen, the latter aziridines have to be activated toward aziridinium ion 
intermediates prior to ring opening [18,19,20,21,22,23,24,25,26,27,28,29,30,31]. Within the 
present work, the scarcely studied subclass of non-activated 1-alkyl-2-
(aminomethyl)aziridines [32,33,34,35,36,37,38,39] was employed as a source of substrates 
for the development of a novel entry toward the biologically relevant 1,2,3-triaminopropane 
unit through a highly regioselective and microwave-assisted ring opening by diethylamine in 
acetonitrile. 
 
Results and discussion – Synthesis 
Given the recently disclosed antimalarial properties of aminopropanols [7,8,9], and taking 
structure-activity relationship studies with regard to chloroquine into account [40], the 
elaboration of a 1,2,3-triaminopropane unit substituted with an aryl group, a N,N-
diethylamino moiety and an azaheteroaromatic nucleus was envisaged as a potential novel 
antimalarial pharmacophore. From a retrosynthetic point of view, 2-(aminomethyl)aziridines 
can be regarded as suitable precursors for the preparation of 1,2,3-triaminopropanes through 
ring opening by amines. Thus, the synthesis of properly substituted aziridines, bearing an 
azaheteroaromatic group in their side chain, was proposed, which then could serve as eligible 





At first, a variety of 2-(aminomethyl)aziridines 2 was prepared via coupling of different 
nitrogen nucleophiles with 2-(bromomethyl)aziridines 1 [41,42,43], employing the 
electrophilicity of the latter as a convenient handle for their connection to other moieties [33]. 
In order to introduce structural diversity within the amino side chain, aziridines 1 were 
connected to different classes of aromatic azaheterocycles such as adenine [44], thymine and 
1,2,4-triazole en route to the corresponding 2-(aminomethyl)aziridines 2a-h (Scheme 1, Table 
1). In addition, also diethylamine was used for the preparation of 2-(N,N-
diethylaminomethyl)aziridines 2i-k in order to evaluate the difference between the presence 
of an aromatic azaheterocyclic moiety and a simple acyclic amino group in 1,2,3-
triaminopropanes with regard to their biological activity. 
 
The synthesis of 2-[(6-aminopurin-9-yl)methyl]aziridines 2a-c was accomplished upon 
treatment of 2-(bromomethyl)aziridines 1 with 1 equiv of adenine in DMF at 80 °C for 5 
hours in the presence of 5 equiv of K2CO3 (Table 1, entries 1-3). Next to the desired N9-
substituted adenines 2a-c, isomeric N7-alkylation products were observed as well in minor 
amounts (N9/N7 ~3/1), which is in accordance with literature data on the N-alkylation of 
adenine [45]. The premised adenine derivatives 2a-c were isolated in pure form through 
crystallization. In recent years, the synthesis of functionalized adenines has gained much 
interest due to the pronounced biological activities, such as antitumor and antiviral, associated 
to this class of compounds [46,47,48]. Besides purines, also pyrimidines are known to be of 
importance as lead compounds in medicinal chemistry [48,49,50]. In that respect, thymine 
was used as a nucleophile toward the preparation of 2-[(2,4-dioxo-5-methylpyrimidin-1-
yl)methyl]aziridines 2d,e upon treatment of 2-(bromomethyl)aziridines 1 with one equiv of 
thymine and one equiv of NaH in DMF at 80 °C for 3 hours (Table 1, entries 4-5). The former 
aziridines 2d,e were obtained in good crude yields, and were purified by crystallization from 
CH2Cl2/Et2O (4/1) in order to obtain analytically pure samples (the yields in Table 1 are 
yields obtained after purification). 
 
Next to DNA bases, the 1,2,4-triazole moiety was introduced as an aziridine side chain 
through reaction of aziridines 1 with 5 equiv of 1,2,4-triazole [51] in CH3CN under reflux for 
2.5 d in the presence of 4 equiv of K2CO3, affording the corresponding triazoles 2f-h in good 
yields (Table 1, entries 6-8) [33]. These long reaction times appeared to be necessary in order 
to drive the reaction to completion. Finally, a number of 2-(N,N-
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diethylaminomethyl)aziridines 2i-k were prepared in good yields using an excess (16 equiv) 
of diethylamine in methanol under reflux for one day (Table 1, entries 9-11). 
 
 
Scheme 1. Synthesis of 2-(aminomethyl)aziridines 2 and their microwave-assisted conversion 




















20 equiv Et2NH HCl
10 equiv Et2NH
CH3CN, 140 °C, 2 h
microwave (200 Wmax)
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Subsequently, 2-(aminomethyl)aziridines 2a-k were converted into novel 1,2,3-
triaminopropanes 3a-k bearing a diethylamino group through elaboration of the constrained 
aziridine moiety. The interest in this type of compounds stems from the known antimalarial 
activity of aminopropanols on the one hand and the relevance of a diethylamino unit in potent 
antimalarial agents (e.g. chloroquine) on the other hand. With the intention to introduce a 
diethylamino group, the ring opening of aziridines 2 by diethylamine was envisaged. Given 
the necessary activation of non-activated aziridines prior to ring opening, the use of 
diethylamine hydrochloride was contemplated. In this way, protonation of the aziridine ring 
provides a highly electrophilic aziridinium intermediate which is prone to nucleophilic ring 
opening. In order to drive the reaction to completion, and to avoid competition between 
chloride- and diethylamine-induced ring opening, a large excess of Et2NH HCl (20 equiv) and 
an additional amount of diethylamine (10 equiv) was used. Nonetheless, only partial 
conversion (<80%) of aziridines 2 was achieved after heating under reflux for 7 days in 
acetonitrile under the given reaction conditions. Fortunately, the poor reactivity of 2-
(aminomethyl)aziridines 2 with regard to the Et2NH HCl/Et2NH system under conventional 
heating was easily overcome through the application of microwave irradiation. Heating of the 
latter aziridines 2 at 140 °C (200 Wmax) in CH3CN resulted in full and selective conversion to 
the desired triaminopropanes 3 after 2 hours (Scheme 1), which were purified by 
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crystallization or column chromatography (Al2O3) in order to obtain analytically pure samples 
(13-65% yield). 
 










1 Ph Adenine A 2a (31%) 
2 4-ClC6H4 Adenine A 2b (51%) 
3 4-MeOC6H4 Adenine A 2c (32%) 
4 4-ClC6H4 Thymine B 2d (34%) 
5 4-MeOC6H4 Thymine B 2e (26%) 
6 Ph 1,2,4-triazole C 2f (90%) 
7 4-ClC6H4 1,2,4-triazole C 2g (63%) 
8 4-MeOC6H4 1,2,4-triazole C 2h (54%) 
9 Ph Et2NH D 2i (90%) 
10 4-ClC6H4 Et2NH D 2j (63%) 
11 4-MeOC6H4 Et2NH D 2k (64%) 
a
 Reaction conditions: A = 1 equiv adenine, 5 equiv K2CO3, DMF, 80 °C, 5 h; B = 1 equiv thymine, 1 
equiv NaH, DMF, 80 °C, 3 h; C = 5 equiv 1,2,4-triazole, 4 equiv K2CO3, CH3CN, , 2.5 d; D = 16 
equiv Et2NH, MeOH, , 1 d 
b
 Yield after purification by crystallization or column chromatography 
 
For aziridines 2a-h, bearing an aromatic azaheterocyclic side chain, the ring opening of 
intermediate aziridinium ions 4a-h proceeded with excellent regioselectivity through attack at 
the unhindered aziridinium carbon atom (Scheme 2). In the case of 2-(N,N-
diethylaminomethyl)aziridines 2i-k, however, a mixture of regioisomers (~3/2 3i-k/6i-k) was 
obtained, with the major isomers 3i-k being formed through ring opening of the initially 
formed aziridinium salts 4i-k at the less hindered position (Scheme 2, pathway a). Due to the 
presence of a nucleophilic nitrogen atom in the diethylaminomethyl group, rearrangement of 
aziridinium salts 4i-k to the corresponding 1,1-diethylaziridinium intermediates 5 occurred as 
well. Then, ring opening by diethylamine at the unhindered aziridinium carbon atom took 
place, giving rise to the formation of 1-(arylmethyl)amino-2,3-bis(diethylamino)propanes 6 
(Scheme 2, pathway b). Only the major isomers 3i-k were isolated in pure form through 
column chromatography on aluminium oxide. 
The observed regioselectivity was confirmed through detailed spectroscopic analysis of 
triaminopropanes 3. In addition, the formation of symmetric compounds 3i-k further 
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corroborates the regiochemical ring opening of aziridinium salts 4 by diethylamine at the 
unsubstituted carbon atom. 
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Results and discussion – Biological evaluation 
Both classes of compounds, i.e. 2-(aminomethyl)aziridines 2 and 1,2,3-triaminopropanes 3, 
were screened for in vitro antiplasmodial activity. All samples were tested in triplicate on one 
occasion against a chloroquine sensitive (CQS) strain of P. falciparum (D10). Additionally, 
those samples showing promising antimalarial activity were tested in triplicate on one 
occasion against a chloroquine-resistant (CQR) strain of P. falciparum (Dd2) and screened for 
in vitro cytotoxicity against a mammalian cell-line, Chinese Hamster Ovarian (CHO), in 
triplicate on one occasion. 
The test samples were prepared to a 2 mg/mL stock solution in 10% DMSO and sonicated to 
enhance solubility. The samples were tested as a suspension and stock solutions were stored at 
-20ºC. Further dilutions were prepared on the day of the experiment. 
 
Antiplasmodial assay 
Continuous in vitro cultures of asexual erythrocyte stages of P. falciparum were maintained 
using a modified method of Trager and Jensen [52]. Quantitative assessment of 
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antiplasmodial activity in vitro was determined via the parasite lactate dehydrogenase assay 
using a modified method described by Makler [53]. Chloroquine diphosphate (Sigma) (CQ) 
was used as the reference drug in all experiments. A full dose-response was performed for all 
compounds to determine the concentration inhibiting 50% of organism growth (IC50-value). 
 
Cytotoxicity assay 
The MTT-assay [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-assay] is used 
as a colorimetric assay for cellular growth and survival, and compares well with other 
available assays [54,55]. The tetrazolium salt MTT was used to measure all growth and 
chemosensitivity. Emetine dihydrochloride (Sigma) was used as the reference drug in all 
experiments. 
 
The results of the biological evaluation are summarized in Table 2 for 2-
(aminomethyl)aziridines 2 and in Table 3 for 1,2,3-triaminopropanes 3. 
Although the aziridine moiety was initially not considered as a template for biological 
screening, both 2-[(1,2,4-triazol-1-yl)methyl]aziridine 2h and 2-(N,N-
diethylaminomethyl)aziridines 2i-k exhibited antiplasmodial activity against the CQS D10 
strain of P. falciparum, with IC50-values between 15.3 and 4.2 M (Table 2). Moreover, 
aziridines 2h and 2i-k also showed antimalarial activity against the CQR Dd2 strain of P. 
falciparum (IC50-values between 48.3 and 18.0 M), and low (2i-k) or no (2h) cytotoxicity 
(Table 2). 
 
With regard to the screening of 1,2,3-triaminopropanes 3, all representatives showed weak to 
potent antiplasmodial activities against the chloroquine sensitive (CQS) strain of P. 
falciparum, with IC50-values ranging from 214.1 to 2.0 M (Table 3), with some degree of 
cross resistance being displayed by 3h. In particular, triazoles 3g,h and 1,3-
bis(diethylamino)propanes 3j,k exhibited superior antimalarial activities with IC50-values 
between 8.4 and 2.0 M. Furthermore, triazoles 3f-h and 1,3-bis(diethylamino)propanes 3i-k 
were tested against the chloroquine-resistant (CQR) strain of P. falciparum, again showing 
antiplasmodial activities. Interestingly, the in vitro cytotoxicity results showed that only 
compounds 3j and 3k have SI‟s of 9 and 24, respectively (Table 3), whereas all other 




Table 2. IC50-values of 2-(aminomethyl)aziridines 2 tested for in vitro antiplasmodial 


































































4.18 (n=2) 23.17 >400 5.6 ND 
2i Ph Et2NH 15.25 48.32 401.67 3.2 26.3 
2j 4-ClC6H4 Et2NH 6.49 23.74 247.33 3.7 38.1 
2k 4-MeOC6H4 Et2NH 8.54 (n=2) 18.04 193.15 2.1 22.6 
CQ   0.040 (n=3) 0.298  7.5  
emetine     0.145   
a
 RI (Resistance Index) = IC50 Dd2/IC50 D10 
b
 SI (Selectivity Index) = IC50 CHO/IC50 D10 
ND = not determined 








Table 3. IC50-values of 1,2,3-triaminopropanes 3 tested for in vitro antiplasmodial 


































































1.98 80.90 158.62 41.1 ND 
3i Ph Et2NH 23.67 30.16 >300 1.3 ND 
3j 4-ClC6H4 Et2NH 8.41 19.82 76.37 2.4 9.1 
3k 4-MeOC6H4 Et2NH 6.66 13.53 170.00 2.0 24.2 




 7.27  
emetine     0.127 (n=2)   
a
 RI (Resistance Index) = IC50 Dd2/IC50 D10 
b
 SI (Selectivity Index) = IC50 CHO/IC50 D10 
ND = not determined 







It should be stressed that a number of 2-(aminomethyl)aziridines (e.g. 2h,j,k) and 1,2,3-
triaminopropanes (e.g. 3g,h,j,k), with IC50-values less than 10 M, exhibited better 
antiplasmodial activities as compared to the previously reported class of aminopropanols [8], 
pointing to the promising potential of aziridines 2 and aminopropanes 3 within the context of 
the development of novel antimalarial agents. In that respect, structure/activity relationship 
studies should be performed as well in the future. It is noteworthy that these compounds were 
synthesized in racemic form, and it is conceivable that enantiomerically pure variants could 
deliver superior activities. 
 
With regard to structure activity relationships, substituted propanes bearing a 1,2,4-triazole 
group at the 1-position, a 4-chloro- or 4-methoxybenzylamino substituent at the 2-position 
and a N,N-diethylamino moiety at the 3-position appear to be of particular interest in terms of 
their antimalarial activity. In addition, 1,3-bis(diethylamino)propanes bearing a 4-chloro- or 
4-methoxybenzylamino substituent at the 2-position are also of importance in that respect. 
 
In conclusion, a novel synthetic protocol was established for the straightforward conversion of 
a variety of 2-(aminomethyl)aziridines into 1,2,3-triaminopropanes through microwave-
assisted regioselective ring opening by diethylamine using a combination of Et2NH HCl and 
Et2NH in acetonitrile. Furthermore, both 2-(aminomethyl)aziridines and 1,2,3-
triaminopropanes were shown to be of biological relevance as potential antimalarial agents, in 
particular 2-[(1,2,4-triazol-1-yl)methyl]aziridines and 2-(N,N-diethylaminomethyl)aziridines 
as well as the corresponding 1-(diethylamino)propanes obtained through ring opening by 
diethylamine. Both the 2-(aminomethyl)aziridine and the 1,2,3-triaminopropane unit can thus 





H NMR spectra were recorded at 300 MHz (JEOL ECLIPSE+) with CDCl3 as solvent and 
tetramethylsilane as internal standard. 
13
C NMR spectra were recorded at 75 MHz (JEOL 
ECLIPSE+) with CDCl3 as solvent and tetramethylsilane as internal standard. Mass spectra 
were obtained with a mass spectrometer Agilent 1100, 70 eV. IR spectra were measured with 
a Spectrum One FT-IR spectrophotometer. Elemental analyses were performed with a 
PerkinElmer series II CHNS/O analyzer 2400. Dichloromethane was distilled over calcium 
hydride, while diethyl ether was dried over sodium benzophenone ketyl. Other solvents were 
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used as received from the supplier. Melting points of crystalline compounds were measured 
with a Büchi 540 apparatus. The purity of all new compounds was assessed by means of 
NMR analysis (purity > 95%). 
Microwave reactions. All microwave reactions were performed in a CEM Focused 
Microwave
TM
 Synthesis System, Model Discover, with a selectable power output from 0 to 300 
Watt. The reactions were performed in 10 mL thick walled Pyrex reaction vessels closed with 
a „snap-on‟ septa cap and equipped with a small stirring bar. The temperature control uses a 
non-contact infrared sensor to measure the temperature on the bottom of the vessel and is used 
in a feedback loop with the on-board computer to regulate the temperature from 25 to 250 °C 
by adjusting the power output (1-Watt increments). The pressure control, IntelliVent
TM
 
Pressure Control System, uses an indirect measurement of the pressure by sensing changes in 
the external deflection of the septa on the top of the sealed pressure vessel. Stirring is 
performed by a rotating magnetic plate located below the floor of microwave cavity. Cooling 
of the vessel after the reaction is performed by a stream of clean air onto the vessel which 
decreases the temperature of a 2 mL solution from 150 °C to 40 °C in less than 120 seconds. 
A ramp time of maximum 5 minutes is used during which the temperature increases from 
room temperature to the desired one. This temperature is maintained during the course of the 
reaction for the indicated time. 
 
Synthesis of 2-(6-aminopurin-9-yl)methyl-1-(arylmethyl)aziridines (2a-c). General 
procedure: To a solution of 1-arylmethyl-2-(bromomethyl)aziridine 1 [41,42,43] (5 mmol) 
and adenine (5 mmol, 1 equiv) in dimethylformamide (50 mL) was added potassium 
carbonate (25 mmol, 5 equiv). After stirring for 5 h at 80 °C, the solvent was removed under 
reduced pressure. The residue was poured into water (25 mL), extracted with CHCl3 (3 x 25 
mL) and washed with brine (3 x 25 mL). The combined organic layers were dried over 
anhydrous magnesium sulfate. Filtration of the drying agent and removal of the solvent in 
vacuo afforded the crude products 2a-c, which were purified by recrystallization. 
2-(6-Aminopurin-9-yl)methyl-1-(phenylmethyl)aziridine (2a). Recrystallization from 
CH2Cl2/Et2O (4/1); yield 31%; mp = 145.2 °C. 
1
H NMR (300 MHz, CDCl3): δ 1.64 (1H, d, J 
= 6.6 Hz), 1.89 (1H, d, J = 3.3 Hz), 2.07-2.13 (1H, m), 3.06 and 3.63 (2H, 2 × d, J = 12.6 Hz), 
3.77 (1H, d × d, J = 14.3, 8.3 Hz), 4.50 (1H, d × d, J = 14.3, 3.9 Hz), 5.87 (2H, br s), 7.09-
7.21 (4H, m), 7.64 and 8.34 (2H, 2 × s). 
13
C NMR (75 MHz, CDCl3): δ 33.2, 37.7, 46.8, 64.4, 
119.5, 127.4, 128.2, 128.4, 138.2, 140.7, 149.8, 152.9, 155.6. IR (ATR, cm
-1
): νNH = 3289 and 
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3103. MS (70 eV): m/z (%) 281 (M
+
 + 1, 100). Anal. calcd for C15H16N6: C 64.27, H 5.75, N 
29.90; found: C 64.06, H 5.74, N 29.73.  
2-(6-Aminopurin-9-yl)methyl-1-[(4-chlorophenyl)methyl]aziridine (2b). Recrystallization 
from CH2Cl2; yield 51%; mp = 167.6 °C. 
1
H NMR (300 MHz, CDCl3): δ 1.64 (1H, d, J = 6.1 
Hz), 1.91 (1H, d, J = 3.3 Hz), 2.06-2.14 (1H, m), 2.91 and 3.62 (2H, 2 × d, J = 12.9 Hz), 3.72 
(1H, d × d, J = 14.3, 8.3 Hz), 4.50 (1H, d × d, J = 14.3, 3.9 Hz), 5.72 (2H, br s), 6.97-7.00 and 
7.08-7.11 (4H, 2 × m), 7.64 and 8.34 (2H, 2 × s). 
13
C NMR (75 MHz, CDCl3): δ 33.4, 37.7, 
46.7, 63.6, 119.4, 128.4, 129.4, 133.1, 136.6, 140.5, 149.6, 152.8, 155.5. IR (ATR, cm
-1
): νNH 
= 3311 and 3119. MS (70 eV): m/z (%): 315/7 (M
+
 + 1, 100). Anal. calcd for C15H15ClN6: C 
57.24, H 4.80, N 26.70; found: C 57.04, H 4.97, N 26.85. 
2-(6-Aminopurin-9-yl)methyl-1-[(4-methoxyphenyl)methyl]aziridine (2c). 
Recrystallization from CH2Cl2/Et2O (4/1); yield 32%; mp = 181.1 °C. 
1
H NMR (300 MHz, 
CDCl3): δ 1.63 (1H, d, J = 6.6 Hz), 1.87 (1H, d, J = 3.3 Hz), 2.04-2.11 (1H, m), 2.93 and 3.60 
(2H, 2 × d, J = 12.6 Hz), 3.72 (1H, d × d, J = 14.3, 8.6 Hz), 3.78 (3H, s), 4.49 (1H, d × d, J = 
14.3, 3.8 Hz), 5.52 (2H, br s), 6.65-6.70 (2H, m), 6.97-7.01 (2H, m), 7.65 and 8.34 (2H, 2 × 
s). 
13
C NMR (75 MHz, CDCl3): δ 33.1, 37.5, 46.9, 55.3, 63.8, 113.7, 119.4, 129.4, 130.4, 
140.7, 149.7, 152.8, 155.6, 158.8. IR (ATR, cm
-1
): νNH = 3310 and 3121. MS (70 eV): m/z 
(%): 311 (M
+
 + 1, 100). Anal. calcd for C16H18N6O: C 61.92, H 5.85, N 27.08; found: C 
61.45, H 5.97, N 26.91. 
 
Synthesis of 1-arylmethyl-2-[(2,4-dioxo-5-methylpyrimidin-1-yl)methyl]aziridines (2d-e). 
General procedure: To a solution of 1-arylmethyl-2-(bromomethyl)aziridine 1 [41,42,43] (5 
mmol) and thymine (5 mmol, 1 equiv) in dimethylformamide (25 mL) was added sodium 
hydride (60% in mineral oil; 5 mmol, 1 equiv). After stirring for 3 h at 80 °C, the solvent was 
removed under reduced pressure. The residue was poured into water (10 mL), extracted with 
chloroform (3 x 15 mL) and washed with brine (3 x 15 mL). The combined organic layers 
were dried over anhydrous magnesium sulfate. Filtration of the drying agent and removal of 
the solvent in vacuo afforded the crude products 2d-e, which were purified by 
recrystallization from dichloromethane/ether (4/1). 
1-(4-Chlorophenyl)methyl-2-[(2,4-dioxo-5-methylpyrimidin-1-yl)methyl]aziridine (2d). 
Recrystallization from CH2Cl2/Et2O (4/1); yield 34%; mp = 149.4 °C. 
1
H NMR (300 MHz, 
CDCl3): δ 1.64 (1H, d, J = 6.1 Hz), 1.74 (3H, d, J = 1.1 Hz), 1.86 (1H, d, J = 3.9 Hz), 2.00-
2.07 (1H, m), 2.79 (1H, d, J = 12.1 Hz), 2.86 (1H, d × d, J = 14.2, 8.8 Hz), 3.87 (1H, d, J = 
12.1 Hz), 4.35 (1H, d × d, J = 14.2, 3.1 Hz), 6.81 (1H, d, J = 1.1 Hz), 7.16-7.21 and 7.23-7.27 
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(4H, 2 × m), 9.42 (1H, br s). 
13
C NMR (75 MHz, CDCl3): δ 12.2, 32.4, 37.5, 51.1, 63.5, 
110.0, 128.6, 130.0, 133.5, 136.9, 140.7, 151.0, 164.2. IR (ATR, cm
-1
): νCO = 1698 and 1660, 
νNH = 3192. MS (70eV): m/z (%): 306/8 (M
+
 + 1, 100). Anal. calcd for C15H16ClN3O2: C 
58.92, H 5.27, N 13.74; found: C 59.31, H 5.46, N 13.46. 
2-(2,4-Dioxo-5-methylpyrimidin-1-yl)methyl-1-[(4-methoxyphenyl)methyl]aziridine (2e). 
Recrystallization from CH2Cl2/Et2O (4/1); yield 26%; mp = 167.7 °C. 
1
H NMR (300 MHz, 
CDCl3): δ 1.64 (1H, d, J = 6.6 Hz), 1.67 (3H, s), 1.84 (1H, d, J = 3.3 Hz), 1.99-2.05 (1H, m), 
2.60 (1H, d, J = 12.1 Hz), 2.71 (1H, d × d, J = 14.3, 9.4 Hz), 3.79 (3H, s), 3.90 (1H, d, J = 
12.1 Hz), 4.41 (1H, d × d, J = 14.3, 2.7 Hz), 6.73 (1H, s), 6.77-6.79 (2H, m), 7.11-7.14 (2H, 
m), 8.92 (1H, br s). 
13
C NMR (75 MHz, CDCl3): δ 12.2, 32.4, 37.8, 51.3, 55.2, 63.8, 109.7, 
113.8, 129.9, 130.5, 140.7, 150.9, 159.0, 164.3. IR (ATR, cm
-1
): νCO = 1696 and 1660, νNH = 
3189. MS (70 eV): m/z (%): 302 (M
+ 
+ 1, 100). Anal. calcd for C16H19N3O3: C 63.77, H 6.36, 
N 13.94; found: C 63.46, H 5.99, N 13.46. 
 
Synthesis of 1-arylmethyl-2-[(1,2,4-triazol-1-yl)methyl]aziridines (2f-h) [33]. General 
procedure: To a solution of 1-arylmethyl-2-(bromomethyl)aziridine 1 [41,42,43] (7.78 mmol) 
and 1,2,4-triazole (38.9 mmol, 5 equiv) in acetonitril (100 mL) was added potassium 
carbonate (31.12 mmol, 4 equiv), after which the resulting suspension was heated under 
reflux for 2 days. Afterwards, the solvent was removed under reduced pressure. The residue 
was poured into 75 mL of 1 M sodium hydroxide solution and extracted with diethyl ether (3 
x 30 mL). The combined organic layers were dried over anhydrous potassium carbonate. 
Filtration of the drying agent and removal of the solvent in vacuo afforded the crude products 
2f-h, which were purified by column chromatography on silica gel (CHCl3/MeOH 97/3). 
1-(4-Methoxyphenyl)methyl-2-[(1,2,4-triazol-1-yl)methyl]aziridine (2h). Rf = 0.17 
(CHCl3/MeOH 97/3); yield 54%. 
1
H NMR (300 MHz, CDCl3): δ 1.60 (1H, d, J = 6.6 Hz), 
1.81 (1H, d, J = 3.3 Hz), 1.99-2.06 (1H, m), 3.19 and 3.44 (2H, 2 × d, J = 12.6 Hz), 3.78 (3H, 
s), 3.91 (1H, d × d, J = 14.2, 7.7 Hz), 4.30 (1H, d × d, J = 14.2, 4.2 Hz), 6.79-6.83 (2H, m), 
7.09-7.13 (2H, m), 7.86 and 7.96 (2H, 2 × s). 
13
C NMR (75 MHz, CDCl3): δ 32.6, 37.5, 52.6, 
55.2, 63.5, 113.9, 129.3, 130.4, 143.1, 151.6, 158.9. IR (ATR, cm
-1
): νmax = 2836, 1612, 1511, 
1273, 1244, 1176, 1139, 1031, 817, 751, 733, 679. MS (70 eV): m/z (%): 245 (M
+ 
+ 1, 100). 
Anal. calcd for C13H16N4O: C 63.91, H 6.60, N 22.93; found: C 63.78, H 6.67, N 22.78. 
 
Synthesis of 1-arylmethyl-2-(diethylaminomethyl)aziridines (2i-k). General procedure: A 
solution of 1-arylmethyl-2-(bromomethyl)aziridine 1 [41,42,43] (6.67 mmol) and 
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diethylamine (106.72 mmol, 16 equiv) in methanol (100 mL) was heated under reflux for 3 
days. Afterwards, the reaction mixture was neutralized by means of a saturated sodium 
bicarbonate solution. The resulting suspension was poured into water (70 mL) and extracted 
with CH2Cl2 (3 x 50 mL). The combined organic layers were dried over anhydrous potassium 
carbonate. Filtration of the drying agent and removal of the solvent under reduced pressure 
afforded the crude products 2i-k, which were purified by column chromatography on silica 
gel. 
2-(N,N-Diethylamino)methyl-1-(phenylmethyl)aziridine (2i). Rf = 0.14 (CHCl3/MeOH 
95/5); yield 90%. 
1
H NMR (300 MHz, CDCl3): δ 0.97 (6H, t, J = 7.2 Hz), 1.40 (1H, d, J = 6.6 
Hz), 1.60 (1H, d, J = 3.3 Hz), 1.63-1.70 (1H, m), 2.38-2.62 (6H, m), 3.34 and 3.46 (2H, 2 × d, 
J = 13.2 Hz), 7.20-7.39 (5H, m).
 13
C NMR (75 MHz, CDCl3): δ 11.6, 32.7, 38.0, 47.0, 56.2, 
64.7, 127.1, 128.4, 139.1. IR (ATR, cm
-1
): νmax = 2968, 2799, 2360, 2341, 1454, 1348, 1202, 
1069, 1028, 757, 731, 697. MS (70 eV): m/z (%): 219 (M
+
 + 1, 100). Anal. calcd for 
C14H22N2: C 77.01, H 10.16, N 12.83; found: C 76.79, H 10.03, N 12.77. 
1-(4-Chlorophenyl)methyl-2-[(N,N-diethylamino)methyl]aziridine (2j). Rf = 0.22 
(CHCl3/MeOH 95/5); yield 63%. 
1
H NMR (300 MHz, CDCl3): δ 0.99 (6H, t, J = 7.2 Hz), 
1.42 (1H, d, J = 6.6 Hz), 1.63 (1H, d, J = 3.9 Hz), 1.66-1.71 (1H, m), 2.47-2.64 (6H, m), 3.33 
and 3.46 (2H, 2 × d, J = 13.5 Hz), 7.30 (5H, s).
 13
C NMR (75 MHz, CDCl3): δ 11.41, 32.61, 
37.99, 46.89, 56.02, 63.79, 128.44, 129.58, 132.80, 137.55. IR (ATR, cm
-1
): νmax = 2970, 
1491, 1346, 1202, 1087, 1071, 1015, 806, 732. MS (70 eV): m/z (%): 253/5 (M
+
 + 1, 100). 
Anal. calcd for C14H21ClN2: C 66.52, H 8.37, N 11.08; found: C 66.67, H 8.62, N 10.99. 
2-(N,N-Diethylamino)methyl-1-[(4-methoxyphenyl)methyl]aziridine (2k). Rf = 0.07 
(CHCl3/MeOH 95/5); yield 64%.
1
H NMR (300 MHz, CDCl3): δ 0.99 (6H, t, J = 7.2 Hz), 1.43 
(1H, d, J = 6.1 Hz), 1.60 (1H, d, J = 3.3 Hz), 1.65-1.70 (1H, m); 2.43-2.64 (6H, m), 3.33 and 
3.41 (2H, 2 × d, J = 13.2 Hz), 3.80 (3H, s), 6.84-6.88 (2H, m), 7.25-7.28 (2H, m). 
13
C NMR 
(75 MHz, CDCl3): δ 11.5, 32.5, 37.7, 46.9, 55.3, 56.1, 64.1, 113.8, 129.4, 131.2, 158.8. IR 
(ATR, cm
-1
): νmax = 2970, 2933, 1612, 1512, 1463, 1300, 1244, 1174, 1035, 819, 730. MS (70 
eV): m/z (%): 249 (M
+
 + 1, 100). Anal. calcd for C15H24N2O: C 72.54, H 9.74, N 11.28; 
found: C 72.43, H 9.84, N 11.16. 
 
Synthesis of 1-(6-aminopurin-9-yl)-2-(arylmethyl)amino-3-diethylaminopropanes (3a-c). 
General procedure: In a 10 mL thick walled Pyrex reaction vessel, 2-(6-aminopurin-9-
yl)methyl-1-(arylmethyl)aziridine 2a-c (0.89 mmol), diethylamine (17.8 mmol) and 
diethylamine hydrochloride (8.9 mmol) were dissolved in acetonitrile (6 mL). The mixture 
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was heated to 140 °C for 2 h under microwave irradiation (200 Wmax). Afterwards, the 
reaction mixture was neutralized by means of a saturated sodium bicarbonate solution, poured 
into water (15 mL), extracted with diethyl ether (3 x 10 mL) and washed with brine (3 x 10 
mL). The combined organic layers were dried over anhydrous potassium carbonate. Filtration 
of the drying agent and removal of the solvent in vacuo afforded the crude products 3a-c, 
which were purified by recrystallization from CH2Cl2/Et2O (4/1). 
1-(6-Aminopurin-9-yl)-3-diethylamino-2-(phenylmethyl)aminopropane (3a). 
Recrystallization from CH2Cl2/Et2O (4/1); yield 34%; mp = 114.7 °C. 
1
H NMR (300 MHz, 
CDCl3): 0.90 (3H, t, J = 7.2 Hz), 1.86 (1H, br s), 2.18-2.51 (6H, m), 3.04-3.09 (1H, m), 3.71 
and 3.79 (2H, 2 × d, J = 13.2 Hz), 4.19 (1H, d × d, J = 13.9, 5.0 Hz), 4.24 (1H, d × d, J = 
13.9, 4.7 Hz), 5.59 (2H, br s), 7.23-7.33 (5H, m), 7.96 and 8.37 (2H, 2 × s). 
13
C NMR (75 
MHz, CDCl3): δ 11.7, 45.7, 46.9, 52.1, 54.7, 55.4, 119.6, 127.0, 128.1, 128.4, 140.2, 142.0, 
150.3, 152.9, 155.3. IR (ATR, cm
-1
): νNH = 3286, 3228, 3130. MS (70 eV): m/z (%): 354 (M
+
 
+ 1, 100). Anal. calcd for C19H27N7: C 64.56, H 7.70, N 27.74; found: C 64.83, H 7.85, N 
27.49. 
1-(6-Aminopurin-9-yl)-2-[(4-chlorophenyl)methyl]amino-3-diethylaminopropane (3b). 
Recrystallization from CH2Cl2/Et2O (4/1); yield 18%; mp = 135.5 °C. 
1
H NMR (300 MHz, 
CDCl3): 0.92 (6H, t, J = 7.2 Hz), 1.80 (1H, br s), 2.21-2.52 (6H, m), 3.01-3.09 (1H, m), 3.68 
and 3.75 (2H, 2 × d, J = 13.5 Hz), 4.17 (1H, d × d, J = 14.1, 5.3 Hz), 4.23 (1H, d × d, J = 
14.1, 4.7 Hz), 5.61 (2H, br s), 7.15-7.18 and 7.23-7.25 (4H, 2 × m), 7.93 and 8.37 (2H, 2 × s). 
13
C NMR (75 MHz, CDCl3): δ 11.7, 45.9, 47.0, 51.4, 54.6, 55.4, 119.4, 128.5, 129.4, 132.7, 
138.6, 141.8, 150.6, 152.9, 155.4. IR (ATR, cm
-1
): νNH = 3284 and 3132. MS (70 eV): m/z 
(%): 388/90 (M
+
 + 1, 100). Anal. calcd for C19H26ClN7: C 58.83, H 6.67, N 25.28; found: C 
58.72, H 7.14, N 24.96.  
1-(6-Aminopurin-9-yl)-3-diethylamino-2-[(4-methoxyphenyl)methyl]aminopropane (3c). 
Recrystallization from CH2Cl2/Et2O (4/1); yield 13%; mp = 106.8 °C. 
1
H NMR (300 MHz, 
CDCl3): 0.91 (3H, t, J = 7.2 Hz), 2.20-2.52 (6H, m), 3.03-3.11 (1H, m), 3.65 and 3.73 (2H, 2 
× d, J = 13.2 Hz), 3.79 (3H, s); 4.19 (1H, d × d, J = 14.5, 5.2 Hz), 4.23 (1H, d × d, J = 14.5, 
4.4 Hz), 5.85 (2H, br s), 6.81-6.85 (2H, m), 7.14-7.18 (2H, m), 7.97 and 8.37 (2H, 2 × s). 
13
C 
NMR (75 MHz, CDCl3): δ 11.7, 45.8, 46.9, 51.5, 54.5, 55.3, 55.4, 113.8, 129.3, 119.3, 132.2, 
141.9, 150.6, 152.9, 155.4, 158.7. IR (ATR, cm
-1
): νNH = 3322 and 3159. MS (70 eV): m/z 
(%): 384 (M
+
 + 1, 100). Anal. calcd for C20H29N7O: C 62.64, H 7.62, N 25.57; found: C 





yl)propanes (3d-e). The procedure for the synthesis of compounds 3a-c was applied for the 
preparation of 2-(arylmethyl)amino-3-diethylamino-1-(2,4-dioxo-5-methylpyrimidin-1-
yl)propanes 3d-e. The crude products 3d-e were purified by column chromatography on 
aluminum oxide or by recrystallization. 
2-[(4-Chlorophenyl)methyl]amino-3-diethylamino-1-(2,4-dioxo-5-methylpyrimidin-1-yl)-
propane 3d. Recrystallization from CH2Cl2/Et2O (4/1); yield 18%; mp = 42.1 °C. 
1
H NMR 
(300 MHz, CDCl3): 0.95 (3H, t, J = 6.9 Hz), 1.90 (3H, s), 2.30-2.54 (6H, m), 2.89-2.94 (1H, 
m), 3.63-3.77 (4H, m), 7.10 (1H, s), 7.19-7.29 (4H, m), 8.86 (1H, br s). 
13
C NMR (75 MHz, 
CDCl3): δ 11.8, 12.2, 47.0, 50.9, 51.5, 54.2, 55.3, 109.6, 128.6, 129.4, 132.8, 138.8, 142.2, 
151.2, 164.2. IR (ATR, cm
-1
): νCO = 1706 and 1660, νNH = 3248. MS (70 eV): m/z (%): 379/81 
(M
+
 + 1, 100). Anal. calcd for C19H27ClN4O2: C 60.23, H 7.18, N 14.79; found: C 60.55, H 
7.42, N 14.57. 
3-Diethylamino-1-(2,4-dioxo-5-methylpyrimidin-1-yl)-2-[(4-methoxyphenyl)methyl]-
aminopropane 3e. Rf = 0.08 (CH2Cl2/MeOH); yield 65%. 
1
H NMR (300 MHz, CDCl3): 0.94 
(3H, t, J = 7.2 Hz), 1.90 (3H, s), 2.32-2.53 (6H, m), 2.90-2.98 (1H, m), 3.65-3.74 (4H, m), 
3.77 (3H, s), 7.13 (1H, s), 6.82-6.85 (2H, m), 7.13 (1H, s), 7.17-7.20 (2H, m). 
13
C NMR (75 
MHz, CDCl3): δ 11.7, 12.3, 46.9, 50.9, 51.5, 53.8, 55.2, 55.3, 109.5, 113.8, 129.4, 132.3, 
142.2, 151.7, 158.6, 165.0. IR (ATR, cm
-1
): νCO = 1674, νNH = 3172 and 3029. MS (70eV): 
m/z (%): 375 (M
+
 + 1, 100). Anal. calcd for C20H30N4O3: C 64.15, H 8.07, N 14.96; found: C 
63.97, H 8.21, N 14.82. 
 
Synthesis of 2-(arylmethyl)amino-3-diethylamino-1-(1,2,4-triazol-1-yl)propanes (3f-h). 
The procedure for the synthesis of compounds 3a-c was applied for the preparation of 2-
(arylmethyl)amino-3-diethylamino-1-(1,2,4-triazol-1-yl)propanes 3f-h. The crude products 
3f-h were purified by column chromatography on aluminum oxide (CH2Cl2/MeOH 99/1). 
3-Diethylamino-2-(phenylmethyl)amino-1-(1,2,4-triazol-1-yl)propane 3f. Rf = 0.54 
(CH2Cl2/MeOH 99/1); yield 40%. 
1
H NMR (300 MHz, CDCl3): 0.91 (6H, t, J = 6.9 Hz), 2.27 
(1H, d × d, J = 14.2, 6.3 Hz), 2.30 (1H, d × d, J = 14.2, 8.3 Hz), 2.34-2.48 (4H, m), 3.00-3.08 
(1H, m), 3.64 and 3.69 (2H, 2 × d, J = 13.5 Hz), 4.12 (1H, d × d, J = 14.0, 5.2 Hz), 4.21 (1H, 
d × d, J = 14.0, 4.7 Hz), 7.20-7.36 (5H, m), 7.93 and 8.13 (2H, 2 × s). 
13
C NMR (75 MHz, 
CDCl3): δ 11.7, 46.9, 51.9, 52.0, 54.6, 55.2, 127.0, 128.1, 140.1, 144.1, 151.6. IR (ATR, cm
-
1
): νNH = 3300. MS (70 eV): m/z (%): 288 (M
+
 + 1, 100). Anal. calcd for C16H25N5: C 66.86, H 
8.77, N 24.37; found: C 66.94, H 8.95, N 24.42. 
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2-[(4-Chlorophenyl)methyl]amino-3-diethylamino-1-(1,2,4-triazol-1-yl)propane 3g. Rf = 
0.12 (CH2Cl2/MeOH 99/1); yield 31%. 
1
H NMR (300 MHz, CDCl3): 0.93 (6H, t, J = 7.2 Hz, 
), 2.27 (1H, d × d, J = 12.8, 6.3 Hz), 2.31 (1H, d × d, J = 12.8, 8.3 Hz), 2.33-2.53 (4H, m), 
3.00-3.08 (1H, m), 3.60 and 3.64 (2H, 2 × d, J = 13.5 Hz), 4.13 (1H, d × d, J = 13.9, 5.8 Hz), 
4.23 (1H, d × d, J = 13.9, 4.4 Hz), 7.16-7.23 and 7.26-7.29 (4H, 2 × m), 7.94 and 8.14 (2H, 2 
× s). 
13
C NMR (75 MHz, CDCl3): δ 11.7, 47.0, 51.3, 52.0, 54.6 55.2, 128.5,129.4, 132.7, 
138.6, 144.1, 151.7. IR (ATR, cm
-1
): νNH = 3290. MS (70 eV): m/z (%): 322/4 (M
+
 + 1, 100). 
Anal. calcd for C16H24ClN5: C 59.71, H 7.52, N 21.76; found: C 59.83, H 7.68, N 21.74. 
3-Diethylamino-2-[(4-methoxyphenyl)methyl]amino-1-(1,2,4-triazol-1-yl)propane 3h. Rf 
= 0.20 (CH2Cl2/MeOH 99/1); yield 19%. 
1
H NMR (300 MHz, CDCl3): 0.93 (6H, t, J = 7.2 
Hz), 2.29-2.32 (2H, m), 2.35-2.50 (4H, m), 3.04-3.06 (1H, m), 3.59 and 3.64 (2H, 2 × d, J = 
12.7 Hz), 3.80 (3H, s), 4.11-4.26 (2H, m), 6.84-6.87 (2H, m), 7.16-7.19 (2H, m), 7.95 and 
8.16 (2H, 2 × s). 
13
C NMR (75 MHz, CDCl3): δ 11.6, 46.9, 51.5, 52.0, 54.5, 55.2, 55.3, 113.9, 
129.3, 132.1, 144.2, 151.7, 158.7. IR (ATR, cm
-1
): νNH = 3311. MS (70 eV): m/z (%): 318 (M
+
 
+ 1, 100). Anal. calcd for C17H27N5O: C 64.32, H 8.57, N 22.06; found: C 64.45, H 8.73, N 
12.89. 
 
Synthesis of 2-(arylmethyl)amino-1,3-bis(diethylamino)propanes (3i-k). The procedure 
for the synthesis of compounds 3a-c was applied for the preparation of 2-(arylmethyl)amino-
1,3-bis(diethylamino)propanes 3i-k. The crude products 3i-k were purified by column 
chromatography on aluminum oxide (CH2Cl2/MeOH 99/1). 
1,3-Bis(diethylamino)-2-(phenylmethyl)aminopropane 3i. Rf = 0.10 (CH2Cl2/MeOH 99/1); 
yield 31%. 
1
H NMR (300 MHz, CDCl3): 0.98 (12H, t, J = 7.2 Hz), 2.39-2.53 (12H, m), 2.66-
2.74 (1H, m), 3.87 (2H, s), 7.28-7.34 (5H, m). 
13
C NMR (75 MHz, CDCl3): δ 12.0, 47.6, 52.0, 
52.7, 57.1, 126.9, 128.4, 128.5, 140.8. IR (ATR, cm
-1
): νNH = 3295. MS (70 eV): m/z (%): 292 
(M
+
 + 1, 100). Anal. calcd for C18H33N3: C 74.14, H 11.41, N 14.42; found: C 74.03, H 11.36, 
N 14.30. 
2-[(4-Chlorophenyl)methyl]amino-1,3-bis(diethylamino)propane 3j. Rf = 0.16 
(CH2Cl2/MeOH 99/1); yield 25%. 
1
H NMR (300 MHz, CDCl3): 0.98 (12H, t, J = 7.2 Hz), 
2.37-2.55 (12H, m), 2.59-2.71 (1H, m), 3.83 (2H, s), 7.18-7.29 (4H, m). 
13
C NMR (75 MHz, 
CDCl3): δ 11.9, 47.5, 51.3, 52.7, 57.1, 128.4, 129.5, 132.4, 139.5. IR (ATR, cm
-1
): νNH = 
3288. MS (70 eV): m/z (%): 326/8 (M
+
 + 1, 100). Anal. calcd for C18H32ClN3: C 66.33, H 
9.90, N 12.89; found: C 66.57, H 10.13, N 12.77. 
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1,3-Bis(diethylamino)-2-[(4-methoxyphenyl)methyl]aminopropane 3k. Rf = 0.19 
(CH2Cl2/MeOH 99/1); yield 13%. 
1
H NMR (300 MHz, CDCl3): 1.00 (12H, t, J = 7.2 Hz), 
2.41-2.58 (12H, m), 2.64-2.81 (1H, m), 3.80 (3H, s), 3.90 (2H, s), 6.86-6.89 (2H, m), 7.25-
7.31 (2H, m). 
13
C NMR (75 MHz, CDCl3): δ 11.6, 47.3, 50.5, 52.2, 55.3, 56.3, 113.9, 129.7, 
130.3, 158.8. IR (ATR, cm
-1
): νNH = 3298. MS (70 eV): m/z (%): 322 (M
+
 + 1, 100). Anal. 
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